Novel hyaluronidase PH20 variant having increased enzymatic activity and expression

A novel PH20 variant with selective amino acid substitutions addresses the limitations of current PH20 variants by enhancing enzyme activity and expression, improving drug absorption and diffusion in subcutaneous tissue for effective drug delivery and cancer treatment.

WO2026235289A1PCT designated stage Publication Date: 2026-11-12GENECHEM
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/004962
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-03-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current recombinant PH20 hyaluronidase variants used for subcutaneous drug delivery have low enzyme activity and expression levels, stability issues, and may cause immunogenicity due to excessive amino acid substitutions, limiting their effectiveness in enhancing drug absorption and diffusion.

Method used

A novel PH20 variant with selective amino acid substitutions at specific positions in the wild-type PH20 protein sequence, improving enzyme activity and expression efficiency.

Benefits of technology

The PH20 variant exhibits enhanced enzyme activity and expression levels, facilitating better drug absorption and diffusion in subcutaneous tissue, suitable for subcutaneous formulation-based polymer therapeutics and cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026004962_12112026_PF_FP_ABST
    Figure KR2026004962_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel hyaluronidase PH20 variant. The PH20 variant according to the present invention exhibits functionally excellent characteristics due to improved enzyme activity and expression level, and thus can be effectively utilized in an injectable composition, a pharmaceutical composition for cancer treatment, a drug delivery substance, or the like.
Need to check novelty before this filing date? Find Prior Art

Description

Novel hyaluronidase PH20 variant with increased enzyme activity and expression

[0001] The present invention relates to a novel human hyaluronidase variant that enhances the enzymatic activity and expression of human hyaluronidase, a hyaluronic acid hydrolyzing enzyme.

[0002] With the recent surge in the development of polymer therapeutics, including antibody drugs, the development of formulations and administration technologies to effectively deliver these drugs to patients has emerged as a critical task. Antibody drugs generally require high doses and are mostly administered via intravenous (IV) injection. However, IV injections take a long time to administer (usually 60 to 90 minutes or more), require significant medical personnel and resources during the preparation and administration process, and place a considerable burden on patients. Consequently, subcutaneous injection (SC) is attracting attention as an alternative that can simultaneously consider patient convenience and medical efficiency.

[0003] Subcutaneous injection has the advantage of allowing for relatively simple and rapid drug administration, but it has limitations such as slow absorption into the body and the potential for pain or swelling at the injection site if a certain volume (3 to 5 mL or more) is exceeded. In particular, for polymer drugs, diffusion and absorption within subcutaneous tissue are limited, which imposes restrictions on dosage and efficacy. As a strategy to overcome these limitations, the co-administration of hyaluronidase is being attempted, and in fact, subcutaneous formulations based on this are being commercialized for some treatments.

[0004] Hyaluronidase functions to reduce the viscosity of the extracellular matrix (ECM) and promote the diffusion of substances within tissues by degrading hyaluronic acid present in the ECM. This can enhance the penetration and absorption of high-molecular-weight drugs into subcutaneous tissue, and when used alone, it is utilized for edema relief and improving the diffusion of local anesthetics. It is known that a total of six types of hyaluronidase exist in humans (HYAL1, HYAL2, HYAL3, HYAL4, HYALP1, SPAM1 / PH20). Among these, PH20 is an enzyme specifically expressed in the cell membrane and acrosome membrane of sperm, and it possesses the characteristic of maintaining activity over a wide pH range of 3 to 8. Such pH stability and high enzymatic activity have led PH20 to attract attention as a key enzyme in drug delivery systems.

[0005] Currently used recombinant PH20 has low expression yields and limitations in maintaining stability and enzymatic activity under physiological conditions. Furthermore, concerns have been raised that PH20 variants, which improve enzymatic activity and thermal stability by introducing multiple amino acid substitutions into the wild-type PH20 protein, may cause side effects such as increased immunogenicity and decreased expression due to excessive substitutions. Therefore, there is a recent demand for the design of variants that can maximize enzymatic activity and expression levels with minimal substitutions, and strategies to ensure stability and efficiency through conservative substitutions are particularly recognized as important.

[0006] Accordingly, the present invention aims to provide a PH20 variant that simultaneously improves enzyme activity and protein expression levels by introducing selective amino acid substitutions to functional core sites in the amino acid sequence of wild-type PH20. Based on improved biological characteristics and industrial productivity compared to the existing PH20, this variant can be applied in various fields, such as the delivery of subcutaneous formulation-based polymer therapeutics, combination administration of anticancer drugs, tissue regeneration, and improvement of absorption rates of other therapeutic agents.

[0007] The inventors prepared a PH20 variant with improved enzyme activity and expression by substituting a specific amino acid sequence of the wild-type PH20 protein, and confirmed that the PH20 variant according to the present invention exhibits superior enzyme activity compared to the existing wild type in in vitro experiments, and that cell expression efficiency also significantly increased.

[0008] Accordingly, the objective of the present invention is to provide a novel PH20 variant with improved enzyme activity and expression levels.

[0009] Another objective of the present invention is to provide an injectable composition, a pharmaceutical composition for cancer treatment, and a drug delivery material comprising a novel PH20 variant.

[0010] The present invention relates to a PH20 variant in which one or more amino acid substitutions are introduced at specific positions in the amino acid sequence of a wild-type PH20 protein. It was experimentally confirmed that the PH20 variant according to the present invention has increased enzyme activity and significantly improved expression efficiency.

[0011] The present invention will be described in more detail below.

[0012]

[0013] One aspect of the present invention is a PH20 variant comprising a mutation in which the amino acid sequence included in wild-type hyaluronidase PH20 is substituted.

[0014] The term “hyaluronidase” as used in this specification is one of the enzymes that decomposes hyaluronic acid, and is a substance that decomposes hyaluronic acid to reduce its viscosity and widen the space between tissues.

[0015] The term “PH20” in this specification is an enzyme that cleaves the β-1,4 bond between acetylglucosamine and glucuronic acid of hyaluronic acid. Currently, commercially widely used PH20 is in the form extracted from the testes of cattle or sheep, and includes ampadase (bovine hyaluronidase) and vitrase (sheep hyaluronidase), among others, and rHuPH20, pegylated rHuPH20, etc. are used, but are not limited thereto.

[0016] rHuPH20 is a recombinant hyaluronidase based on the human-derived PH20 gene. It has high biocompatibility and low immunogenicity, making it suitable for use as a subcutaneous adjuvant.

[0017] The term “variant” as used herein refers to a polypeptide in which one or more amino acids are conservatively substituted and / or modified, resulting in a sequence of amino acids different from that of the variant prior to modification, while retaining functions or properties. Such variants can generally be identified by modifying one or more amino acids in the amino acid sequence of the polypeptide and evaluating the properties of the modified polypeptide. That is, the capabilities of the variant may be increased, unchanged, or decreased compared to the polypeptide prior to modification. Additionally, some variants may include variants in which one or more parts, such as an N-terminal leader sequence or a transmembrane domain, have been removed. Other variants may include variants in which a portion of the N- and / or C-terminus of a mature protein has been removed. The term "variant" mentioned above may be used interchangeably with terms such as variant, modification, variant polypeptide, mutated protein, mutation, and variant (in English, modification, modified polypeptide, modified protein, mutant, mutein, divergent, etc.), and is not limited to these terms as long as they are used with the meaning of being mutated.

[0018] Additionally, the variant may include deletions or additions of amino acids that have minimal effect on the properties and secondary structure of the polypeptide. For example, a signal (or leader) sequence involved in co-translational or post-translational protein translocation may be conjugated to the N-terminus of the variant. Additionally, the variant may be conjugated with another sequence or linker to enable identification, purification, or synthesis.

[0019] The PH20 variant according to the present invention may include a mutation in which some or all of the sequences included in the 340th to 354th amino acids of SEQ ID NO. 1 are substituted with the 322nd to 336th amino acid sequences of SEQ ID NO. 2.

[0020] Specifically, the PH20 variant of the present invention may include a mutation in which some or all of the sequences included in the 341st to 353rd amino acids of SEQ ID NO. 1 are substituted with the 323rd to 335th amino acid sequences of SEQ ID NO. 2.

[0021] In one embodiment of the present invention, nine PH20 variants (GCP-101 to GCP-109) were constructed in which all or part of the amino acids within the range of glycine (G), the 340th amino acid of SEQ ID NO. 1, to leucine (L), the 354th amino acid, of the wild-type PH20 were substituted with all or part of the amino acid sequence within the range of valine (V), the 322nd amino acid, to isoleucine (I), the 336th amino acid, which corresponds to the site of wild-type Hyal1 of SEQ ID NO. 2 (see Example 1). After constructing the PH20 variants, the Morgan-Elson method and Western blot were performed, respectively, to determine the enzymatic activity and expression levels of the proteins (see Examples 2 and 3). Experimental results showed that the expression efficiency and enzyme activity of the variant (GCP-105), in which all amino acids of the T341 to L353 segment of SEQ ID NO. 1 were substituted with the 323rd to 335th amino acid sequence of Hyal1 of SEQ ID NO. 2, were significantly increased compared to the wild type PH20, but compared to the variant having the sequence of SEQ ID NO. 3, the enzyme activity and expression were slightly increased or similar.

[0022] In one embodiment of the present invention, nine PH20 variants (GCP-110 to GCP-118) were constructed in which additional amino acid substitutions were introduced at positions corresponding to isoleucine (I), the 344th amino acid of SEQ ID NO. 1, and leucine (L), the 353rd amino acid of SEQ ID NO. 1, in order to develop variants with improved expression efficiency and enzyme activity compared to the PH20 variant of SEQ ID NO. 8 (GCP-105). The constructed PH20 variants were analyzed for enzyme activity and expression levels (see SEQ ID NO. 2 and 3). The experimental results showed that the expression efficiency and enzyme activity of variants (GCP-110, GCP-116, and GCP-117) containing substitutions of amino acid residues I344Q, L353K, or L353R of SEQ ID NO. 1 were significantly increased compared to the variant having the sequence of SEQ ID NO. 3. GCP-119 and GCP-120 variants, in which two amino acids were simultaneously substituted, showed enhanced enzyme activity and expression compared to GCP-110, GCP-116, and GCP-117 variants, in which one amino acid was substituted.

[0023] In one embodiment of the present invention, 32 PH20 variants (GCP-119 to GCP-150) were constructed to investigate the effect of additional amino acid substitution of serine (S), the 343rd amino acid of SEQ ID NO. 1, and lysine (K), the 349th amino acid, on enzyme activity and expression (see Example 1). The constructed PH20 variants were analyzed for enzyme activity and expression levels (see Examples 2 and 3). As a result of the experiment, the 32 PH20 variants composed of the amino acid sequences of SEQ ID NOs. 22 to 53 generally exhibited enzyme activity and expression similar to that of the GCP-119 and GCP-120 variants.

[0024] The PH20 variant according to the present invention may include a mutation in which glycine (G), the 340th amino acid of sequence number 1, is substituted with valine (V).

[0025] The PH20 variant according to the present invention may include a mutation in which threonine (T), the 341st amino acid of sequence number 1, is substituted with serine (S).

[0026] The PH20 variant according to the present invention may include a mutation in which leucine (L), the 342nd amino acid of sequence number 1, is substituted with tryptophan (W).

[0027] The PH20 variant according to the present invention may include a mutation in which serine (S), the 343rd amino acid of sequence number 1, is substituted with aspartic acid (D), glutamic acid (E), lysine (K), or glutamine (Q).

[0028] The PH20 variant according to the present invention may include a mutation in which isoleucine (I), the 344th amino acid of sequence number 1, is substituted with aspartic acid (D), histidine (H), lysine (K), leucine (L), asparagine (N), glutamine (Q), or serine (S).

[0029] The PH20 variant according to the present invention may include a mutation in which methionine (M), the 345th amino acid of sequence number 1, is substituted with threonine (T).

[0030] The PH20 variant according to the present invention may include a mutation in which serine (S), the 347th amino acid of sequence number 1, is substituted with threonine (T).

[0031] The PH20 variant according to the present invention may include a mutation in which methionine (M), the 348th amino acid of sequence number 1, is substituted with lysine (K).

[0032] The PH20 variant according to the present invention may include a mutation in which lysine (K), the 349th amino acid of sequence number 1, is substituted with aspartic acid (D), glutamic acid (E), or glutamine (Q).

[0033] The PH20 variant according to the present invention may include a mutation in which leucine (L), the 352nd amino acid of sequence number 1, is substituted with glutamine (Q).

[0034] The PH20 variant according to the present invention may include a mutation in which leucine (L), the 353rd amino acid of sequence number 1, is substituted with alanine (A), lysine (K), glutamine (Q), or arginine (R).

[0035] The PH20 variant according to the present invention may include a mutation in which leucine (L), the 354th amino acid of sequence number 1, is substituted with isoleucine (I).

[0036] Specifically, the PH20 variant according to the present invention may be a PH20 variant having the amino acid sequence of SEQ ID NOs 4 to 53.

[0037] In addition, the PH20 variant according to the present invention may be a PH20 variant in which the 341st to 353rd amino acid sequence of SEQ ID NO. 1 is X1X2X3QTRX4KX5SCX6X7.

[0038] Specifically, X1 is S or T, X2 is W or L, X3 is E, D, K or Q, X4 is S or T, X5 is K, E, D or Q, X6 is L or Q, and X7 is A, K or R, and there may be PH20 variants.

[0039] More specifically, it may be a PH20 variant of the amino acid sequence of SEQ ID NOs 8 to 53.

[0040] Specifically, there may be a PH20 variant in which X1 is S, X2 is W, X3 is E, D, K or Q, X4 is T, X5 is K, E, D or Q, X6 is Q, and X7 is A, K or R.

[0041] More specifically, it may be a PH20 variant which is the amino acid sequence of SEQ ID NO. 13 or 22 to 53.

[0042] Specifically, X1 is S, X2 is W, X3 is E, D, K or Q, X4 is T, X5 is K, E, D or Q, X6 is Q, and X7 is K or R, which may be PH20 variants.

[0043] More specifically, it may be a PH20 variant of the amino acid sequence of SEQ ID NOs 22 to 53.

[0044] The PH20 variant according to the present invention may include an amino acid sequence having 95% or more sequence homology with the amino acid sequences of SEQ ID NOs 4 to 53.

[0045] Specifically, the PH20 variant according to the present invention may include a polypeptide having at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% homology or identity with any one of the amino acid sequences in the group consisting of 4 to 53.

[0046] Furthermore, it is obvious that a protein having an amino acid sequence in which some sequences are deleted, modified, substituted, or added is also included within the scope of the present invention, provided that such an amino acid sequence possesses such homology or identity and exhibits efficacy corresponding to the said protein.

[0047] More specifically, the PH20 variant according to the present invention may include any one of the amino acid sequences of SEQ ID NOs 13 or 22 to 53.

[0048] More specifically, the PH20 variant according to the present invention may comprise any one of the amino acid sequences of SEQ ID NOs 22 to 53.

[0049] The term “mutation” as used herein refers to a change in the sequence of nucleotides or amino acids within a gene compared to the wild type. Such mutations include insertions, deletions, substitutions, point mutations, mutations of multiple nucleotides or amino acids, transpositions, inversions, frame shifts, nonsense mutations, or other forms of modification that differentiate a target sequence from the wild-type sequence of the gene.

[0050] The terms “homology” or “identity” as used herein refer to the degree of relationship between two given amino acid sequences or base sequences and may be expressed as a percentage. The terms homology and identity may often be used interchangeably.

[0051] The sequence homology or identity of conserved polynucleotides or polypeptides is determined by standard arrangement algorithms, and a default gap penalty established by the program used may be utilized. Practically, homologous or identical sequences can be hybridized under moderate or high stringent conditions, generally along at least about 50%, 60%, 70%, 80%, or 90% of the entire sequence or its total length. Hybridization also considers polynucleotides containing degenerate codons instead of codons.

[0052] Whether any two polynucleotide or polypeptide sequences have homology, similarity, or identity can be determined using a known computer algorithm, such as the "FASTA" program, using default parameters, for example. Alternatively, it can be determined using the Needleman-Wunsch algorithm, as performed in the Needleman program of the EMBOSS package (version 5.0.0 or later). For example, homology, similarity, or identity can be determined using BLAST from the National Biotechnology Information Database Center or ClustalW.

[0053] Homology, similarity, or identity of polynucleotides or polypeptides can be determined, for example, by comparing sequence information using a GAP computer program. In summary, the GAP program is defined as the total number of symbols in the shorter of the two sequences divided by the number of similarly arranged symbols (i.e., nucleotides or amino acids). Default parameters for the GAP program may include (1) a binary comparison matrix (containing values ​​of 1 for identity and 0 for non-identity) and a weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap opening penalty of 10, a gap extension penalty of 0.5); and (3) no penalty for terminal gaps.

[0054] In addition, whether any two polynucleotide or polypeptide sequences have homology, similarity, or identity can be determined by comparing the sequences through Southern hybridization experiments under defined strict conditions, and the defined appropriate hybridization conditions are within the scope of the art and can be determined by methods well known to those skilled in the art.

[0055] The PH20 variant according to the present invention may comprise one or more substitution mutations of the amino acid sequences mentioned in the present specification from SEQ ID NO. 1, and may be in a form that is cleaved before the phenylalanine (F) residue, which is the 38th amino acid of the N-terminus of SEQ ID NO. 1, and cleaved after the asparagine (N) residue, which is the 483rd amino acid of the C-terminus.

[0056] Another aspect of the present invention is a vector comprising a polynucleotide encoding the amino acid sequence of a PH20 variant according to the present invention.

[0057] Specifically, it may be a vector comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 4 to 53.

[0058] More specifically, it may be a vector comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO. 13 or 22 to 53.

[0059] More specifically, it may be a vector comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 22 to 53.

[0060] The term “vector” as used herein means a DNA product containing a sequence of nucleotides of a polynucleotide encoding said target polypeptide, which is operably linked to a suitable expression control region (or expression control sequence) so as to enable the expression of said target polypeptide within a suitable host. The expression control region may include a promoter capable of initiating transcription, any operator sequence for regulating such transcription, a sequence coding for a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. After being transformed into a suitable host cell, the vector may replicate or function independently of the host genome and may be incorporated into the genome itself.

[0061] For example, a polynucleotide encoding a target protein can be expressed within a chromosome using a vector for intracellular chromosome insertion. The insertion of said polynucleotide into the chromosome may be achieved by any method known in the art, for example, homologous recombination, but is not limited thereto. A selection marker may be additionally included to confirm whether the chromosome insertion has occurred. The selection marker is intended to select cells transformed by the vector, that is, to confirm whether the target nucleic acid molecule has been inserted, and markers conferring selectable phenotypes such as drug resistance, nutritional requirements, resistance to cytotoxic agents, or the expression of surface proteins may be used. Since only cells expressing the selection marker survive or exhibit other phenotypes in an environment treated with a selective agent, the transformed cells can be selected.

[0062] The vectors used in this application are not particularly limited, and any vector known in the art may be used.

[0063] Examples of vectors commonly used in prokaryotic cells include pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, and Charon21A as phage vectors or cosmid vectors, and pBR-based, pUC-based, pBluescriptII-based, pGEM-based, pTZ-based, pCL-based, and pET-based plasmid vectors. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC, pDCM2 vectors, etc., can be used.

[0064] As an example of a vector used in eukaryotic cells, yeast expression vectors can be both integrative yeast plasmids (YIp) and extrachromosomal plasmid vectors. The extrachromosomal plasmid vectors may include episomal yeast plasmids (YEp), replicative yeast plasmids (YRp), and yeast centrosome plasmids (YCp). Additionally, artificial yeast chromosomes (YACs) may also be used as vectors for the present application. As a specific example, available vectors are pESCHIS, pESC-LEU, pESC-TRP, pESC-URA, Gateway pYES-DEST52, pAO815, pGAPZ A, pGAPZ B, pGAPZ C, pGAPα A, pGAPα B, pGAPα C, pPIC3.5K, pPIC6 A, pPIC6 B, pPIC6 C, pPIC6α A, pPIC6α B, pPIC6α C, pPIC9K, pYC2 / CT, pYD1 Yeast Display Vector, pYES2, pYES2 / CT, pYES2 / NT A, pYES2 / NT B, pYES2 / NT C, pYES2 / CT, pYES2.1, pYES-DEST52, pTEF1 / Zeo, pFLD1, PichiaPinkTM, p427-TEF, p417-CYC, pGAL-MF, p427-TEF, p417-CYC, PTEF-MF, pBY011, pSGP47, pSGP46, pSGP36, pSGP40, ZM552, pAG303GAL-ccdB, pAG414GAL-ccdB, pAS404, pBridge, pGAD-GH, pGAD T7, pGBK T7, pHIS-2, pOBD2, pRS408, pRS410, pRS418, pRS420, pRS428, yeast micron A form, pRS403, pRS404, pRS405, pRS406, pYJ403, pYJ404, Includes, but not limited to, pYJ405 and pYJ406.

[0065] More specifically, the vector in this specification may be pCDNA3.1-Zeo.

[0066] Another aspect of the present invention is a host cell comprising a polynucleotide encoding a PH20 variant according to the present invention.

[0067] Specifically, it may be a host cell comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 4 to 53.

[0068] More specifically, it may be a host cell comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO. 13 or 22 to 53.

[0069] More specifically, it may be a host cell comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 22 to 53.

[0070] Another aspect of the present invention is a host cell comprising a vector containing a polynucleotide encoding a PH20 variant according to the present invention.

[0071] Specifically, it may be a host cell comprising a vector containing a polynucleotide encoding the amino acid sequences of SEQ ID NOs 4 to 53.

[0072] More specifically, it may be a host cell comprising a vector comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO. 13 or 22 to 53.

[0073] More specifically, it may be a host cell comprising a vector containing a polynucleotide encoding the amino acid sequences of SEQ ID NOs 22 to 53.

[0074] Another aspect of the present invention is a host cell transformed with a vector comprising a polynucleotide encoding a PH20 variant according to the present invention.

[0075] Specifically, it may be a host cell transformed with a vector comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 4 to 53.

[0076] More specifically, it may be a host cell transformed with a vector comprising a polynucleotide encoding the amino acid sequence of SEQ ID NO. 13 or 22 to 53.

[0077] More specifically, it may be a host cell transformed with a vector comprising a polynucleotide encoding the amino acid sequences of SEQ ID NOs 22 to 53.

[0078] The term “host cell” as used herein refers to a cell into which exogenous nucleic acid has been introduced (including the offspring of such cell). Host cells include “transformants” and “transformed cells,” which include primary transformed cells and offspring derived therefrom, regardless of the number of passages. The offspring may not have a nucleic acid content identical to that of the parent cell, but may contain mutations. Mutant offspring having the same function or biological activity as those selected from the original transformed cell are included herein. Host cells are any type of cell system that can be used to produce the antibody or bispecific antibody of the present invention. Host cells include cultured cells, for example, mammalian cultured cells, such as HEK cells, CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, and include cells contained within genetically modified animals, genetically modified plants, or cultured plant or animal tissues.

[0079] Specifically, it may be CHO (Chinese hamster ovary) cells, but is not limited to this.

[0080] The term "transformation" as used herein means introducing a vector containing a polynucleotide encoding a target protein into a host cell or microorganism so that the protein encoded by said polynucleotide can be expressed within the host cell. The transformed polynucleotide may include all of the following, regardless of whether it is inserted into or located outside the chromosomes of the host cell, as long as it can be expressed within the host cell. Additionally, said polynucleotide includes DNA and RNA encoding the target protein. said polynucleotide may be introduced in any form that can be introduced into the host cell and expressed. For example, said polynucleotide may be introduced into the host cell in the form of an expression cassette, which is a gene structure containing all the elements necessary for self-expression. said expression cassette may typically include a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to said polynucleotide. said expression cassette may be in the form of a self-replicating expression vector. In addition, the polynucleotide may be introduced into a host cell in its own form and operably linked to a sequence required for expression in the host cell, but is not limited thereto.

[0081] The term “operably connected” as used in this specification means that a promoter sequence and a gene sequence are functionally connected to initiate and mediate the transcription of a polynucleotide encoding the polypeptide of the purpose of this application.

[0082] The method of transforming a vector according to the present invention includes any method of introducing nucleic acid into a cell, and depending on the host cell, a suitable standard technique as known in the art may be selected and performed. Examples include, but are not limited to, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, and lithium acetate-DMSO method.

[0083] Another aspect of the present invention is an injectable composition comprising a PH20 variant according to the present invention.

[0084] Specifically, it may be an injectable composition comprising a PH20 variant of SEQ ID NOs 4 to 53.

[0085] More specifically, it may be an injectable composition comprising a pH 20 variant of SEQ ID NO. 13 or 22 to 53.

[0086] More specifically, it may be an injectable composition comprising a pH 20 variant of SEQ ID NOs 22 to 53.

[0087] The injectable composition according to the present invention may be one or more compositions selected from the group consisting of subcutaneous injection compositions, intramuscular injection compositions, and local anesthetic compositions, but is not limited thereto.

[0088] The term “composition for subcutaneous injection” as used in this specification refers to a component of an injectable preparation for subcutaneous administration. Subcutaneous injection is a method of injecting a drug into the fat layer beneath the skin, allowing the drug to be slowly absorbed to produce a sustained effect. Drugs used for subcutaneous injection may exist in various forms, such as solution, suspension, or emulsion.

[0089] As used herein, the term “composition for intramuscular injection” refers to the compositional components of a drug injected directly into a muscle. Muscle tissue is rich in blood vessels, allowing for rapid absorption of the drug, and some drugs may be designed to provide a sustained-release effect. Intramuscular injections may exist in various forms, such as aqueous solutions, suspensions, and oily formulations.

[0090] The term “local anesthetic” as used in this specification refers to a drug that temporarily blocks or paralyzes sensation by blocking nerve signals in a specific area. Local anesthetics act by blocking the transmission of pain signals through action on nerves and may be used in the form of injections, creams, gels, patches, etc.

[0091] Another aspect of the present invention is a pharmaceutical composition for cancer treatment comprising a PH20 variant according to the present invention.

[0092] Specifically, it may be a pharmaceutical composition for cancer treatment comprising a PH20 variant of SEQ ID NOs 4 to 53.

[0093] More specifically, it may be a pharmaceutical composition for treating cancer comprising a PH20 variant of SEQ ID NO. 13 or 22 to 53.

[0094] More specifically, it may be a pharmaceutical composition for cancer treatment comprising a PH20 variant of SEQ ID NOs 22 to 53.

[0095] The term “pharmaceutical composition” as used in this specification means a composition prepared for the purpose of preventing or treating a disease, and may be formulated into various forms according to conventional methods.

[0096] The content of the PH20 variant of the pharmaceutical composition of the present invention can be appropriately adjusted according to the symptoms of the disease, the degree of progression of symptoms, the condition of the patient, etc. For example, it may be 0.0001 to 99.9% by weight or 0.001 to 50% by weight based on the total weight of the composition, but is not limited thereto. The above content ratio is a value based on the dry weight after removing the solvent.

[0097] The pharmaceutical composition according to the present invention may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions. The excipient may be one or more selected from the group consisting of, for example, diluents, binders, disintegrants, lubricants, adsorbents, humectants, film-coating materials, and controlled-release additives.

[0098] The pharmaceutical composition according to the present invention may be formulated and used in the form of external preparations such as powders, granules, sustained-release granules, enteric granules, liquids, eye drops, oxylic agents, emulsions, suspensions, ethanol tablets, troches, fragrances, limonene adzes, tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, irrigation solutions, warning agents, lotions, pastes, sprays, inhalants, patches, sterile injectable solutions, or aerosols, according to conventional methods, and the external preparations may have formulations such as creams, gels, patches, sprays, ointments, warning agents, lotions, liniments, pastes, or cataplasms.

[0099] Carriers, excipients, and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0100] When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

[0101] Excipients such as corn starch, potato starch, wheat starch, lactose, sucrose, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium monohydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, refined lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropylmethylcellulose, 1928, 2208, 2906, 2910, propylene glycol, casein, calcium lactate, primogel, etc., as additives to tablets, powders, granules, capsules, pills, and lozenges according to the present invention; Gelatin, gum arabic, ethanol, agar powder, cellulose phthalate, carboxymethylcellulose, calcium carboxymethylcellulose, glucose, purified water, sodium casein, glycerin, stearic acid, sodium carboxymethylcellulose, sodium methylcellulose, methylcellulose, microcrystalline cellulose, dextrin, hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, refined shellac, starch paste, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc. may be used as binders, and hydroxypropylmethylcellulose, corn starch, agar powder, methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, Calcium carboxymethylcellulose, calcium citrate, sodium lauryl sulfate, anhydrous silica, 1-hydroxypropylcellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, amylopectin, pectin, sodium polyphosphate, ethylcellulose, sucrose, magnesium aluminum silicate, D-sorbitol solution, hard anhydrous silica, etc. disintegrants;Lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium pods, kaolin, petroleum jelly, sodium stearate, cocoa paste, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, macrogol, synthetic aluminum silicate, anhydrous silica, higher fatty acids, higher alcohols, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and hard anhydrous silica may be used.

[0102] As additives to the liquid formulation according to the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, monostearic acid sucroses, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, lanolin esters, acetic acid, hydrochloric acid, water ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethylcellulose, sodium carboxymethylcellulose, etc. may be used.

[0103] In the syrup preparation according to the present invention, a solution of white sugar, other sugars or sweeteners, etc. may be used, and if necessary, flavorings, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, viscosity enhancers, etc. may be used.

[0104] Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.

[0105] In the suspension agent according to the present invention, suspending agents such as acacia, tragacanthus, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, 1828, 2906, and 2910 may be used, and surfactants, preservatives, stabilizers, coloring agents, and fragrances may be used as needed.

[0106] The injectable preparation according to the present invention comprises solvents such as distilled water for injection, 0.9% sodium chloride injection solution, Ringer's injection solution, dextrose injection solution, dextrose + sodium chloride injection solution, PEG, lactated Ringer's injection solution, ethanol, propylene glycol, non-volatile oils—sesame oil, cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, tween, nijungtinamide, hexamine, and dimethylacetamide; and buffers such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums. It may include isotonic agents such as sodium chloride; stabilizers such as sodium bisulfite (NaHSO3), carbon dioxide gas, sodium metabisulfite (Na2S2O3), sodium sulfite (Na2SO3), nitrogen gas (N2), and ethylenediaminetetraacetic acid; sulfating agents such as sodium bisulfide 0.1%, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetic acid, and sodium bisulfite acetone; non-analizing agents such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; and suspending agents such as sodium CMC, sodium alginate, Tween 80, and aluminum monostearate.

[0107] The suppository according to the present invention comprises cocoa dough, lanolin, Witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cocoa butter + cholesterol, lecithin, lanette wax, glycerol monostearate, Tween or Spandex, Imhausen, monollene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego-G, Cebes Pharma 16, hexalide base 95, Cotomar, Hydroccote SP, S-70-XXA, S-70-XX75 (S-70-XX95). Bases such as Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Masupol, Masupol-15, Neosupostal-N, Paramount-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), suppository base type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wecobi (W, R, S, M, Fs), and Tegestor triglyceride base (TG-95, MA, 57) may be used.

[0108] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the extract. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used.

[0109] Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.

[0110] Another aspect of the present invention is a drug delivery material comprising a PH20 variant according to the present invention.

[0111] Specifically, it may be a drug delivery material comprising a PH20 variant of SEQ ID NOs 4 to 53.

[0112] More specifically, it may be a drug delivery material comprising a pH20 variant of SEQ ID NO. 13 or 22 to 53.

[0113] More specifically, it may be a drug delivery material comprising a PH20 variant of SEQ ID NOs 22 to 53.

[0114] The term “drug delivery material” as used in this specification refers to various physical and chemical systems for effectively delivering a drug to a desired site. Drug delivery materials can help a drug reach a target site within the body and be released continuously and stably. Drug delivery materials may exist in various forms, such as liposomes, nanoparticles, hydrogels, and transdermal drug delivery systems.

[0115] The present invention relates to a novel hyaluronidase PH20 variant. Since the PH20 variant according to the present invention exhibits functionally superior characteristics with improved enzyme activity and expression levels, it can be effectively utilized in injectable compositions, pharmaceutical compositions for cancer treatment, or drug delivery materials.

[0116] Figure 1 shows the Western blot results to confirm the expression of wild-type PH20 and PH20 variants in CHO cells.

[0117] Figure 2 shows the results of a comparative analysis of the enzyme activity of wild-type PH20 and PH20 variants (GCP-101 to GCP-109).

[0118] Figure 3 shows the results of a comparative analysis of the enzyme activity of wild-type PH20 and PH20 variants (GCP-110 to GCP-118).

[0119] A PH20 variant in which the 341st to 353rd amino acid sequences of SEQ ID NO. 1 are X1X2X3QTRX4KX5SCX6X7, wherein X1 is S or T, X2 is W or L, X3 is E, D, K or Q, X4 is S or T, X5 is K, E, D or Q, X6 is L or Q, and X7 is A, K or R.

[0120] The present invention will be explained in more detail below through the following examples. However, these examples are merely illustrative of the invention, and the scope of the invention is not limited by these examples.

[0121]

[0122] Example 1. Preparation of PH20 variant

[0123] 1-1. Creation of Cloning Vector

[0124] To produce hyaluronidase, gene synthesis was performed by optimizing codons in GeneScript so that the wild-type PH20 gene sequence could be efficiently expressed in CHO (Chinese hamster ovary) cells from F38 to N483.

[0125] The specific amino acid sequences of wild-type PH20, wild-type Hyal1, HP46 (conventional improved PH20 variants), and the PH20 variant according to the present invention are as shown in Tables 1 to 14 below. In the amino acid sequences of Tables 1 to 14 below, the underlined sections indicate sequence ranges where substitutions have occurred compared to wild-type PH20, and the amino acids indicated in bold represent the actually substituted residues.

[0126]

[0127]

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

[0137]

[0138]

[0139]

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147]

[0148]

[0149]

[0150]

[0151] 서열번호명칭아미노산 서열 (N term-C term)52GCP-149FRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYVDRLGYYPYIDSITGVTVNGGIPQKISLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWARNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHLWGYYLFPDCYNHHYKKPGYNGSCFNVEIKRNDDLSWLWNESTALYPSIYLNTQQSPVAATLYVRNRVREAIRVSKIPDAKSPLPVFAYTRIVFTDQVLKFLSQDELVYTFGETVALGASGIVIWGSWQQTRTKKSCQRLDNYMETILNPYIINVTLAAKMCSQVLCQEQGVCIRKNWNSSDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDAVDVCIADGVCIDAFLKPPMETEEPQIFYN53GCP-150FRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYVDRLGYYPYIDSITGVTVNGGIPQKISLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWARNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHLWGYYLFPDCYNHHYKKPGYNGSCFNVEIKRNDDLSWLWNESTALYPSIYLNTQQSPVAATLYVRNRVREAIRVSKIPDAKSPLPVFAYTRIVFTDQVLKFLSQDELVYTFGETVALGASGIVIWGSWQQTRTKQSCQRLDNYMETILNPYIINVTLAAKMCSQVLCQEQGVCIRKNWNSSDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDAVDVCIADGVCIDAFLKPPMETEEPQIFYN

[0152]

[0153] The codon-optimized PH20 gene was amplified using Polymerase Chain Reaction (PCR) and inserted into the HindIII and XhoI restriction sites of the pCDNA3.1-Zeo vector. ExpiCHO-S TM For expression in (ThermoFisher, Product No. A29127) cells, human serum albumin was used as the signal peptide instead of the intrinsic signal peptide of PH20, and a 10X His-tag was inserted at the 3'-terminus for protein purification using a HisTrap column.

[0154] The sequences of the primers used for cloning the PH20 variant are as shown in Tables 15 to 18 below.

[0155]

[0156] 서열번호명칭증폭 유전자서열번호방향서열 정보 (5`-3`)541_For1ForGGCTAGCGTTTAAACTTAAGCTT551Rev_Rev 1GCCCTCTAGACTCGAGTTAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTTGTAGAAGATCTGTGGCTCTT561_Rev 2Rev 2ACGGGCCCTCTAGACTCGAGTT571_Has ForHas ForTTCAGCTCTGCTTACTCTTTCAGAGCTCCTCCT58Has Has RevAGAGTAAGCAGAGCTGAAC5922_For22ForCAGACCAGAACCAAAGAATCTTGCCAGAAGCTGGACAACTACATGGAA6022_RevRevTTCTTTGGTTCTGGTCTGCTCCCAAGAGCCCCAGATCAC6123_For23ForAGACTGGACAACATGGACTACAT A6223_RevRevTTCCATGTAGTTGTCCAGTCTCTGGCAAGATTCTTTGGT6324_For24ForCAGACCAGAACCAAAGACTCTTGCCAGAAGCTGGACAACTACATGGAA6424_RevRevGTCTTTGGTTCTGGTCTGCTCCCAAGAGCCCCAGATC6525 _For25ForCAGACCAGAACCAAAGTCTTGCCAGAAGCTGGACAACATACATGGAA6625_RevRevCTTTTTGGTTCTGGTCTGCTCCCAAGAGCCCCAGATCAC6726_For26ForCAGACCAGAACCAAACAGTCTTGCCAGAAGCTGGACAACATACATGGG AA6826_RevRevCTGTTTGGTTCTGGTCTGCTCCCAAGAGCCCCAGATCAC6927_For27ForGACCAGACCAGAACCAAAGAATCTTGCCAGAAGCTGGACAACTACATGGAA7027_RevTTTGGTTCTGGTCTGGTCCCAAGAGCCATCACCATCCATCCATGGAA7027_RevTTTGGTTCTGGTCT

[0157]

[0158] Sequence number name amplification Gene sequence number direction sequence information (5`-3`)7128_For28ForGACCAGACCAGAACCAAAGACTCTTGCCAGAAGCTGGACAACTACATGGAA7228_RevRevTTTGGTTCTGGTCTGGTCCCAAGAGCCCGATCACGAT7329_For29ForGACCAGACCAGAACCAAAAAGTCTTGCCAGAAGCTGGACAACTACATGGAA7429_RevRevTTTGGTTCTGGTCTGGTCCCAAGAGCCCCAGATCACGAT7530_For30ForGACCAGACCAGAACCAAACAGTCTTGCCAGAAGCTGGACAACTACATGGAA7630_RevRevTTTGGTTCTGGTCTGGTCCCAAGAGCCCCAGATCACGAT7731_For31ForCAGACCAGAACCAAAGAATCTTGCCAGAAGCTGGACAACTACATGGAA7831_RevRevTTTGGTTCTGGTCTGCTCCTGCTCCAAGAGCCCCAGA TCACGAT7932_For32ForCAGACCAGAACCAAAGACTCTTGCCAGAAGCTGGACAACTACATGGAA8032_RevRevTTTGGTTCTGGTCTGCTTCCAGAGCCCAGATCAGATCACGAT8133_For33ForCAGACCAGAACCAAAAAGTCTTGCCAGAAGCTGGACAACTACATGGAA8233_RevRevTTTGGTTCTGGTCTGCTTCCAGAGCCCAGATCAGATCACGAT8334_For34ForCAGACCAGAACCAAACAGTCTTGCCAGAAGCTGGACAACTACATGGAA8434_RevRevTTTGGTTCTGGTCTGCTTCCAGAGCCCAGATCAGATCACGAT8535_For35ForCAGACCAGAACCAAAGAATCTTGCCAGAAGCTGGACAACTACATGGAA8635_RevRevTTTGGTTCTGGTCTGCTCTGCTCCCAAGAGCCCAGATCAGATCACGAT

[0159]

[0160]

[0161]

[0162]

[0163]

[0164] 1-2. Protein Expression

[0165] The expression of the variant was performed using the ExpiCHO expression system. The cell number of ExpiCHO-S cells was 6 x 10 6 When the cell count reached cells / mL, the plasmid containing the variant PH20 was transformed into ExpiCHO-S cells using the ExpiFectamine CHO Reagent, and then 25 to 30 ml of cells were cultured with shaking for 4 to 7 days in a 37°C shaker with approximately 80% humidity and 5 to 8% CO2. Upon completion of culture, the cell supernatant was collected by centrifugation at 10,000 rpm for 30 minutes.

[0166] The expressed proteins were confirmed using SDS-PAGE and Western blot.

[0167]

[0168] Example 2. Analysis of enzyme activity of the PH20 variant

[0169] The enzymatic activity of hyaluronidase pH 20 and other hyaluronidases was measured using the following Morgan-Elson method.

[0170] The Morgan-Elson method is a colorimetric method for quantifying (545 nm) a red substance produced by the reaction between the reducing end of N-acetyl-D-glucosamine (GlcNAc), which is generated when hyaluronic acid is hydrolyzed by hyaluronidase, and para-dimethylaminobenzaldehyde (DMAB), which is Ehrlich's reagent. N-acetyl D-glucosamine (GlcNAc, Sigma) was diluted with dilution buffer solution (0.1 M sodium phosphate, 0.1 M sodium chloride, 1.3 mg / ml BSA, pH 6.0) to concentrations of 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, and 20 Mm. Each test tube was treated with tetraborate, heated at 100°C for 5 minutes, and then DMAB was added to induce a color reaction at 37°C for 20 minutes. After the reaction, the absorbance was measured at 545 nm to construct a standard reaction curve for GlcNAc. 5 μl of diluted hyaluronidase solution was added to 125 μl of dilution buffer solution (1.5 mg / ml HA, 0.1 M sodium phosphate, 0.1 M sodium chloride, 1.5 mM saccharic acid 1,4-lactone, pH 6.0) to form the substrate hyaluronic acid, and the mixture was reacted at 37°C for 45 minutes. The enzymatic reaction was terminated by heating at 100°C for 5 minutes, followed by the addition of tetraborate and heating at 100°C for 5 minutes. Afterward, DMAB was added to allow the color development reaction to proceed at 37°C for 20 minutes. After the reaction, the absorbance was measured at 545 nm, and the enzyme activity was determined using the standard reaction curve of GlcNAc above (see Figures 2 and 3).

[0171] As a result, the enzymatic activity of each hyaluronidase PH20 variant was as shown in Tables 19 to 20 below.

[0172]

[0173]

[0174]

[0175] 서열번호명칭아미노산 서열(304~324)상대적인 효소 활성야생형PH20 대비(%)HP46대비(%)35GCP-132GSWQQTRTKESCQKLDNYMETI47016236GCP-133GSWQQTRTKDSCQKLDNYMETI44415337GCP-134GSWQQTRTKKSCQKLDNYMETI44915538GCP-135GSWQQTRTKQSCQKLDNYMETI42614739GCP-136GSWEQTRTKDSCQRLDNYMETI43214940GCP-137GSWEQTRTKKSCQRLDNYMETI45515741GCP-138GSWEQTRTKQSCQRLDNYMETI43515042GCP-139GSWDQTRTKESCQRLDNYMETI45815843GCP-140GSWDQTRTKDSCQRLDNYMETI44915544GCP-141GSWDQTRTKKSCQRLDNYMETI44415345GCP-142GSWDQTRTKQSCQRLDNYMETI45815846GCP-143GSWKQTRTKESCQRLDNYMETI43214947GCP-144GSWKQTRTKDSCQRLDNYMETI42614748GCP-145GSWKQTRTKKSCQRLDNYMETI42114549GCP-146GSWKQTRTKQSCQRLDNYMETI42314650GCP-147GSWQQTRTKESCQRLDNYMETI44415351GCP-148GSWQQTRTKDSCQRLDNYMETI45215652GCP-149GSWQQTRTKKSCQRLDNYMETI46115953GCP-150GSWQQTRTKQSCQRLDNYMETI441152

[0176]

[0177] 실시예 3. PH20 변이체의 발현 분석

[0178] Protein expression was analyzed by measuring enzyme activity as well as performing a western blot using a SPAM1 polyclonal antibody (Invitrogen, PA5-76062) and a His Tag antibody (Invitrogen, MA1-21315) against human PH20. Specifically, after transferring a 10% SDS gel to a nitrocellulose membrane at 100 V for 1 hour, the expression levels of the wild-type PH20 and PH20 variants were measured using the His Tag antibody (Invitrogen, MA1-21315) and an anti-mouse IgG secondary antibody (m-IgGk BP-HRP, Santa Cruz Biotechnology) (see Fig. 1).

[0179] The specific expression levels of variant PH20 are shown in Tables 21 to 23 below.

[0180]

[0181] Sequence No. Name Amino Acid Sequence (340–361) Relative Expression Level Compared to Wild Type PH20 (%) Compared to HP46 (%) 1 Wild Type PH20 GTLSIMRSMKSCLLLDNYMETI100- Sequence No. Name Amino Acid Sequence (322–343) Relative Expression Level Compared to Wild Type PH20 (%) Compared to HP46 (%) 2 Wild Type Hyal1VSWENTRTKESCQAIKEYMDTT-- Sequence No. Name Amino Acid Sequence (303–324) Relative Expression Level Wild Type PH20 Contrast (%)HP46Compare (%)3HP46GSWENTRTKESCQAIKEYMDTT3791004GCP-101GSWENTRSMKSCLLLDNYMETI199535GCP-102GSWENTRTMKSCLLLDNYMETI138366 GCP-103GSWENTRTKKSCLLLDNYMETI241647GCP-104GSWENTRTKESCQLLDNYMETI3841018GCP-105GSWENTRTKESCQALDNYMETI365969GCP-106GSWENT RTKESCQAIDNYMETI2817410GCP-107VSWENTRTKESCQALDNYMETI3749911GCP-108GTWENTRTKESCQALDNYMETI3188412GCP-109GTLENTRTKESCQALDN YMETI2757313GCP-110GSWEQTRTKESCQALDNYMETI39710514GCP-111GSWEKTRTKESCQALDNYMETI3729815GCP-112GSWEDTRTKESCQALDNYMETI36195

[0182]

[0183]

[0184]

[0185] Sequence No. Name Amino Acid Sequence (303–324) Relative Expression Level Compared to Wild Type PH20 (%) Compared to HP46 (%) 44 GCP-141GSWDQTRTKKSCQRLDNYMETI 496 131 45 GCP-142GSWDQTRTKQSCQRLDNYMETI 530 140 46 GCP-143GSWKQTRTKESCQRLDNYMETI 503 133 47 GCP-144GSWKQTRTKDSCQRLDNYMETI 509 134 48 GCP-145GSWKQTRTKKSCQRLDNYMET I51713649GCP-146GSWKQTRTKQSCQRLDNYMETI49413050GCP-147GSWQQTRTKESCQRLDNYMETI48112751GCP-148GSWQQT RTKDSCQRLDNYMETI50613452GCP-149GSWQQTRTKKSCQRLDNYMETI52413953GCP-150GSWQQTRTKQSCQRLDNYMETI509134

[0186] The present invention relates to a novel human hyaluronidase variant that enhances the enzymatic activity and expression of human hyaluronidase, a hyaluronic acid hydrolyzing enzyme.

Claims

1. In a PH20 variant in which the 341st to 353rd amino acid sequences of SEQ ID NO. 1 are X1X2X3QTRX4KX5SCX6X7, The above X1 is S or T; The above X2 is W or L; The above X3 is E, D, K, or Q; The above X4 is S or T; The above X5 is K, E, D, or Q; The above X6 is L or Q; and The above X7 is a PH20 variant that is A, K, or R.

2. In Paragraph 1, The above X1 is S and; The above X2 is W; The above X3 is E, D, K, or Q; The above X4 is T; The above X5 is K, E, D, or Q; The above X6 is Q; and The above X7 is a PH20 variant that is A, K, or R.

3. In Paragraph 1, The above X1 is S and; The above X2 is W; The above X3 is E, D, K, or Q; The above X4 is T; The above X5 is K, E, D, or Q; The above X6 is Q; and The above X7 is a PH20 variant that is K or R.

4. In Paragraph 1, The above PH20 variant is a PH20 variant comprising any one of the amino acid sequences of SEQ ID NO. 13 or 22 to 53.

5. In Paragraph 1, The above PH20 variant is a PH20 variant that is cleaved before the phenylalanine (F) residue, which is the 38th amino acid of the N-terminus of SEQ ID NO. 1, and cleaved after the asparagine (N) residue, which is the 483rd amino acid of the C-terminus.

6. A vector comprising a polynucleotide encoding the PH20 variant of Claim 1.

7. In Paragraph 6, The above vector is a vector that is pCDNA3.1-Zeo.

8. A polynucleotide encoding the PH20 variant of Claim 1; or A vector containing the above polynucleotide; A host cell that includes 9. In Paragraph 8, The above host cell is a CHO (Chinese hamster ovary) cell.

10. An injectable composition comprising the PH20 variant of Claim 1.

11. A pharmaceutical composition for treating cancer comprising the PH20 variant of Claim 1.

12. A drug delivery material comprising a pH 20 variant of Claim 1.